GSK's pill, the first oral antibiotic for urinary tract infections in almost 30 years, comes as bacteria are increasingly ...
The US Food and Drug Administration has approved a new type of antibiotic to treat urinary tract infections. The pill, ...
GSK is opening the door to a new era in urinary tract infection (UTI) treatment with its Blujepa, the first in a new class of ...
This antibiotic is the first new FDA-approved medication for urinary tract infections in decades, and meets the need for new ...
Gepotidacin is an oral, first-in-class triazaacenaphthylene antibiotic that inhibits bacterial DNA replication by blocking 2 different type II topoisomerase enzymes.
The U.S. Food and Drug Administration has approved Blujepa (gepotidacin) for the treatment of uncomplicated urinary tract ...
Blujepa is the first in a new class of oral antibiotics in 30 years. It is expected to launch in the second half of 2025 in the United States.
The FDA has approved GSK’s Blujepa for the treatment of female adults and pediatric patients with uncomplicated urinary tract ...
The Food and Drug Administration (FDA) has approved a new drug for treating urinary tract infections, the first such drug ...
GSK received approval from the Food and Drug Administration for Blujepa to be used as a treatment for some urinary tract infections. Blujepa, or gepotidacin, was approved to treat uncomplicated ...
The drug Blujepa, from drugmaker GSK, provides a new treatment option as bacteria increasingly become resistant to the ...
“The approval of Blujepa is a crucial milestone with uUTIs among the most common infections in women,” said Tony Wood, Chief Scientific Officer, GSK. “We are proud to have developed ...